tbuckley/cabot-search huggingface dataset:
FRI0423 Impact of Disease Activity on Organ Damage Risk Over Time in Systemic Lupus Erythematosus – The Hopkins Lupus Cohort: Table 1.
Authors: R.T. Burge, S. Al Sawah, X. Zhang, Y. Wang, L. Magder, M. Petri
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Disease activity increases the risk of irreversible organ damage in systemic lupus erythematosus (SLE), but estimating that risk in absolute terms is challenging, given disease activity fluctuations, variable disease durations, and the roles of comorbid factors and treatment (corticosteroids) in organ damage. <h3>Objectives</h3> To understand the impact of disease activity (measured by SELENA-SLEDAI score) and proportion of time with a certain level of disease activity (measured by the proportion of clinic visits with disease activity at or above a prespecified SELENA-SLEDAI score) on the risk of developing new irreversible organ damage, as measured by the SLICC/ACR Damage Index (SDI) score. <h3>Methods</h3> Cox proportional hazard models were used to estimate the impact of predictors, including measures of disease activity as time-dependent variables, on the risk of developing any new organ damage over time. <h3>Results</h3> Patients (N=2199) were followed for an average of 6.2 years (mean age at cohort entry, 38.0 years; mean disease duration, 5.1 years). The most frequent types of organ damage occurring over time were ocular (cataract) and musculoskeletal (osteoporotic fractures). In an initial model excluding the variable "proportion of clinic visits with SLEDAI score ≥6", age and SDI score at cohort entry, SLEDAI score (&lt;6 vs. ≥6) during follow-up, and corticosteroid use (&lt;7.5mg/dl vs ≥7.5 mg/day) during follow-up were significant predictors of the risk of developing any new organ damage (Model 1). When including the "proportion of clinic visits with SLEDAI score ≥6" (Model 2), SLEDAI score (&lt;6 vs. ≥6) during follow-up was no longer significant. For Model 3, we excluded the time-dependent variable "SLEDAI score (&lt;6 vs. ≥6) during follow-up" from the model, and the effect of "proportion of clinic visits with SLEDAI score ≥6" was slightly reduced but remained significant. <h3>Conclusions</h3> Organ damage in SLE is multifactorial, with both corticosteroid treatment and disease activity playing roles. However, patients with high levels of disease activity for a greater proportion of the follow-up time had significantly higher organ damage risk compared to those with high levels of disease activity for a lesser proportion of the follow-up time. These findings call for active measures to control disease activity over time in SLE. <h3>Disclosure of Interest</h3> R. Burge Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, S. Al Sawah Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, X. Zhang Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Y. Wang Consultant for: Eli Lilly and Company, Employee of: inVentiv Health Clinical, L. Magder: None declared, M. Petri: None declared
Prostaglandin E2 and lipoxin A4 in PBMCs are associated with immune tolerance during venom immunotherapy
Authors: Zuzanna Lech, Maciej Chalubinski, Slawomir Kosiński, Ewa Smorawska, Claudio Bassin, Cezmi A. Akdis, Janina Grzegorczyk, Marek L. Kowalski
Journal: Journal of Allergy and Clinical Immunology (2016)
Cognitive function after coronary bypass surgery: effect of decreased cerebral blood flow
Authors: A M Freeman, D G Folks, R S Sokol, A V Govier, J G Reves, E L Fleece, K R Hall, G L Zorn, R B Karp
Journal: American Journal of Psychiatry (1985)

The effect of regional cerebral blood flow during coronary bypass surgery on performance on the Mini-Mental State Examination was studied in 14 patients. No association between lowered regional cerebral blood flow and cognitive scores was found.
SP0228 Polyautoimmunity. Diagnosis and Significance
Authors: J.-M. Anaya
Journal: Annals of the Rheumatic Diseases (2015)

Autoimmune diseases (ADs) are chronic and heterogeneous conditions that affect specific target organs or multiple organ systems. They are caused by the interactions over time between hereditary and environmental factors leading to a breakdown in immune tolerance and the ensuing tissue damage. The fact that these disorders share several clinical signs and symptoms (i.e., subphenotypes such as arthritis, alopecia, fatigue, photosensitivity, Raynaud9s phenomenon as well as non-specific autoantibodies, e.g., antinuclear antibodies, rheumatoid factor, anti-Ro antibodies), physiopathological mechanisms (e.g., type I interferon activation, reduced B and T cell regulatory function), and genetic factors at both the MHC and non-MHC loci, has been called the autoimmune tautology and indicates that they have several common mechanisms [1]. One of the strongest arguments supporting the autoimmune tautology is polyautoimmunity, defined as the presence of more than one AD in a single patient [2,3]. When three or more ADs coexist, this extreme phenotype is called multiple autoimmune syndrome (MAS) [4]. Polyautoimmunity has been described in most of the ADs including systemic lupus erythematosus (41%), type 1 diabetes mellitus (35%), Sjögren9s syndrome (33%), primary biliary cirrhosis (32%), antiphospholipid syndrome (28%), vitiligo (27%), systemic sclerosis (26%), autoimmune thyroid diseases (15%), multiple sclerosis (15%), rheumatoid arthritis (15%), myasthenia gravis (13%), and alopecia areata (10%). The main factors associated with polyautoimmunity are familial autoimmunity (i.e., the presence of diverse ADs in a nuclear family) and Amerindian ancestry. Based on polyautoimmunity and depending on severity, ADs may be categorized as major and minor diseases. In this sense, how polyautoimmunity affects major ADs has not fully evaluated. The main difference between polyautoimmunity and the overlapping syndromes lies in the fact that the former is the presence of two well-defined ADs while the later is the partial presence of autoimmune signs and symptoms. Nevertheless, most of the overlapping syndromes evolve over time towards the full spectrum of an AD. When this does not happen, protective factors are considered to be responsible for preventing the progression of the overlapping conditions towards a complete phenotype. The identification of the common mechanisms of ADs through the study of polyautoimmunity will enhance our understanding of these complex, frequent, and sometimes devastating diseases and will allow us to predict them at the population level in order to establish preventive measures for at-risk individuals for whom healthcare should be personalized and participatory. Anaya JM. Arthritis Res Ther. 2010;12:147. Rojas-Villarraga A, et al. Autoimmune Dis. 2012;2012:254319. Anaya JM. Autoimmun Rev. 2014;13:423-6. Anaya JM, el at. Clin Rev Allergy Immunol. 2012;43:256-64. <h3>Disclosure of Interest</h3> None declared
Thrombopoietin receptor agonists shift the balance of Fcγ receptors toward inhibitory receptor IIb on monocytes in ITP
Authors: Xin-guang Liu, Shuang Liu, Qi Feng, Xue-na Liu, Guo-sheng Li, Zi Sheng, Peng Chen, Yang Liu, Yu Wei, Xiao-yuan Dong, Ping Qin, Chengjiang Gao, Chunhong Ma, Lei Zhang, Ming Hou, Jun Peng
Journal: Blood (2016)
Case 23-1988
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, R.A. Arky, C.C. Compton
Journal: New England Journal of Medicine (1988)

Presentation of CaseA 58-year-old woman was admitted to the hospital because of recurrent confusional episodes.She was well until four years earlier, when she began to experience occasional episodes of confusion during which she was unable to perform or to continue tasks for several seconds; the episodes subsided spontaneously and occurred five times in two years. The attacks were not accompanied by palpitation or sweating. During some episodes the patient repeated the same question as many as 30 times, although it had been answered each time. In other attacks she could not arouse herself to act but simply stood . . .
A phase II multicentric trial of S-1 combined with24 h-infusion of cisplatin in patients with advanced gastric cancer
Authors: H. Iwase, M. Shimada, T. Tsuzuki, Y. Horiuchi, S. Kumada, J. Haruta, T. Yamaguchi, K. Ina, K. Kusugami, H. Goto
Journal: Journal of Clinical Oncology (2005)

4055 Background: In Japan, S-1-based chemotherapy is used for the treatment of advanced gastric cancer. The aim of this multicentric trial was to determine the clinical toxicities, antitumor effects of a chemotherapy regimen of S-1 combined with 24-h infusion of cisplatin in patients with high grade advanced gastric cancer. Methods: 42 patients with unresectable locally advanced or metastatic gastric cancer were entered into the multicentric study. S-1 (80 mg/m2) was administered orally a day for 14 consecutive days and 24-h infusion of cisplatin (70 mg/m2) was administered on day 8 without 14 days drug of every 28-day cycle. Results: CR was observed in 2 and PR was observed in 19 patients (CR rate: 4.8% (95% CI: 0.6%–16.2%), PR rate: 45%(95%CI: 29.8%–61.3%)). The overall response rate was 50% (21/42) (95%CI: 32.4%–65.8%). The most common adverse event was leucopenia, which occurred with grade 3 in 7 patients (16.6%) and grade 4 in 2 patients (4.8%). Nonhematologic adverse events were generally mild. Grade 3 nausea and vomiting were observed in 4 patients (9.5%). Grade 3 mucositis, and hand and-foot syndrome were not observed. One patient suffered perforation of the stomach during second chemotherapy. The median survival time was 342 days. The 1-year survival rate was 44.4% (95% CI: 29.2%–59.6%). The 2-year survival rate was 22.9% (95%CI: 9.4%–36.4%). Conclusions: This combination chemotherapy with S-1 and cisplatin is active, convenient, well tolerated and may have the possibility to improve survival in patients with high grade advanced gastric cancer. No significant financial relationships to disclose.
THU0473 Diacerein Reduces Antagonists of WNT Enabling this System's Activity in Human Osteoarthritic Subchondral Bone Osteoblasts
Authors: J. Martel-Pelletier, F. Mineau, D. Hum, J.-P. Pelletier
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Clinical and in vitro studies suggest that altered subchondral bone remodeling is involved in the progression and/or onset of osteoarthritis (OA). Human OA subchondral bone osteoblasts display an abnormal metabolism, including alterations in the Wnt/β-catenin signaling pathway. <h3>Objectives</h3> As therapeutic strategies aimed at modifying the metabolism of subchondral bone may be indicated in the treatment of OA, we investigated diacerein, an anthraquinone, which has been shown to positively impact the abnormal subchondral bone metabolism in OA. Here, we further explored the effect of this drug, and its active metabolite rhein, on elements of the Wnt system in human OA subchondral bone osteoblasts. <h3>Methods</h3> Therapeutic concentrations of diacerein/rhein (5-20 μg/ml) were used to assess their effects on the levels of β-catenin and the Wnt antagonists Dickkopf (DKK)-1 and -2. The β-catenin expression, as well as its nuclei translocation, was assessed after 20 hours of incubation using mRNA and Western blot. DKK-1 and -2 expressions were determined after 20 hours of incubation, and DKK-1 protein production after 48 hours in the culture medium using a specific ELISA. <h3>Results</h3> The RNA level of β-catenin expression was increased in diacerein (p≤0.01) and rhein (p≤0.014) treated cells. For the β-catenin nuclei translocation, the Wnt ligand most potent in bone tissue was added at a concentration of 100 ng/ml, and increased this activity by only 50%. Both diacerein and rhein increased β-catenin nuclei translocation (diacerein, p≤0.04; rhein, p≤0.06). DKK-1 and DKK-2 mRNA expressions were dose-dependently decreased with both drugs (p≤0.009). Compared to DKK-1, the expression level of DKK-2 demonstrated a more marked decrease (90% vs. 60%). Both drugs also markedly and significantly decreased DKK-1 protein levels (p≤0.02) in a dose-dependent manner. <h3>Conclusions</h3> Diacerein and rhein positively impact the abnormal Wnt system in OA by increasing the level of β-catenin in the nuclei. This effect is likely mediated via a decrease in the DKK-1 and -2. This study infers that these drugs may be appropriate for positively modulating the abnormal metabolism of human OA subchondral bone osteoblasts. <h3>Disclosure of Interest</h3> None declared
Further Studies on the Response of Strain a Female Mice to Small Amounts of &lt;italic&gt;o&lt;/italic&gt;-Aminoazotoluene
Authors: Howard B. Andervont
Journal: JNCI Journal of the National Cancer Institute (1947)

Further Studies on the Response of Strain a Female Mice to Small Amounts of o-Aminoazotoluene Howard B. Andervont Howard B. Andervont National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 7, Issue 6, June 1947, Pages 431–432, https://doi.org/10.1093/jnci/7.6.431 Published: 01 June 1947 Article history Received: 25 February 1947 Published: 01 June 1947
PTH-020 Large low rectal vs. high rectal polyps: outcome data from a large prospective series: Abstract PTH-020 Table 1 Factors associated with recurrence
Authors: R Bhattacharyya, F Chedgy, K Kandiah, F Thursby-Pelham, G Longcroft-Wheaton, B Pradeep
Journal: Gut (2015)

<h3>Introduction</h3> Low rectal polyps are challenging to resect. We aim to compare safety, feasibility and outcomes of endoscopic resection of low rectal polyps (within 5 cm of dentate line) versus mid to high rectal polyps. <h3>Method</h3> Cohort study. All patients who had endoscopic resection of rectal polyps &gt;20 mm from 2009 to July 2014 were included. All procedures performed by a single experienced endoscopist. Benign LST-G lesions were resected by conventional EMR technique but polyps close to dentate line, those with scarring, and flat LST-NG lesions were resected either by full ESD or Knife assisted resection technique. <h3>Results</h3> 181 polyps resected in 179 patients. Avg. patient age 71 years. Mean polyp size 50 mm (20–170 mm). Mean follow up 3 years. Referrals were due to large polyp size, proximity to dentate line or haemorrhoidal bed, scarring or &gt;50% circumference involvement. Polyp characteristics: 61/181(33.7%) &gt;50 mm size, 34/181(18.8%) scarred, 109/181(60.2%) in high rectum and 72/181(39.8%) in low rectum. 110/181(60.8%) resected by ESD and 71/181(39.2%) by EMR. 60/181(33.2%) resected en bloc. Histology showed 8(4.4%) cancers and 27(15%) HGD. There was no significant difference between high and low rectal lesions. Follow up was available for 158. Endoscopic cure rate: 147/158(93%). Of these 124/147(84%) required 1 attempt, 17/147(11.5%) required 2 and 6/147(4.5%) required more than 2 attempts for complete cure. Recurrence/residual polyp after first attempt seen in 30/158 (19%) of patients. Univariate analysis showed that recurrence was significantly linked to size &gt;50 mm, piecemeal resection, low rectal lesions and scarring (Table 1). The complication rate was 14/181(7.7%) which were all managed conservatively. There was 1(0.5%) significant intraprocedural bleed. There were 7(3.9%) delayed bleeds (2 needing transfusion), 1(0.5%) post polypectomy syndrome and 5(2.7%) cases of exposed muscle fibres clipped during the procedure with no further sequelae. There were no factors significantly predictive of complications. <h3>Conclusion</h3> Rectal polyps referred for resection are generally very large (mean 50 mm). It is safe and feasible to resect very low rectal polyps around the dentate line. We found no difference in complication rates between low and high rectal polyps. Given large sizes and rectal location, the low cancer rate reflects our careful lesion selection. Recurrence is higher in low rectal polyps and those with large size and scarring. However, repeat attempts can achieve complete clearance. <h3>Disclosure of interest</h3> None Declared.
Does a Multimodal No-Compression Suture Technique of the Intercostal Space Reduce Chronic Postthoracotomy Pain? A Prospective Randomized Study
Authors: Mohsen Ibrahim, Cecilia Menna, Claudio Andreetti, Carlos Puyo, Giulio Maurizi, Antonio D’Andrilli, Anna Maria Ciccone, Domenico Massullo, Camilla Vanni, Giammauro Berardi, Rossella Baldini, Erino Angelo Rendina
Journal: Journal of Thoracic Oncology (2016)
Lymphocytic Choriomeningitis Virus in Mouse Neoplasms
Authors: Sarah E. Stewart, Victor H. Haas
Journal: JNCI Journal of the National Cancer Institute (1956)

Journal Article Lymphocytic Choriomeningitis Virus in Mouse Neoplasms Get access Sarah E. Stewart, Sarah E. Stewart National Cancer Institute,2 and National Institute of Allergy and Infectious Diseases,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar Victor H. Haas Victor H. Haas National Cancer Institute,2 and National Institute of Allergy and Infectious Diseases,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 17, Issue 2, August 1956, Pages 233–245, https://doi.org/10.1093/jnci/17.2.233 Published: 01 August 1956 Article history Received: 10 April 1956 Published: 01 August 1956
Positive In-111 pentetreotide scintigraphy: pulmonary hamartoma.
Authors: ROSEMARY KLECKER, ADINA CIOC, RODNEY POZDERAC
Journal: Clinical Nuclear Medicine (2001)

KLECKER, ROSEMARY J. M.D.,*; CIOC, ADINA M. M.D.†; POZDERAC, RODNEY V. M.D.‡ Author Information
THU0272 Diagnostic Performance and Disease Activity Assessment by FDG-PET in Large-Vessel Vasculitis: A Systematic Literature Review and Meta-Analysis
Authors: M. Soussan, P. Nicolas, C. Schramm, S. Katsahian, O. Fain, A. Mekinian
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> We aimed to clarify the role of FDG-PET in the management of large-vessel vasculitis, focusing on three issues i) describe and determine the different FDG-PET criteria for the diagnosis of vascular inflammation ii) the performance of FDG-PET for the diagnosis of large-vessel inflammation in GCA patients and iii) the performance of FDG-PET to evaluate the disease inflammatory activity in TA patients. <h3>Methods</h3> MEDLINE, Cochrane Library and EMBASE database were searched for articles that evaluated the value of FDG-PET in large-vessel vasculitis, from 01/2000 to 12/2013. Inclusion criteria were: American College of Rheumatology (ACR) criteria for GCA or TA, definition PET positivity threshold, and &gt;4 cases included. Sensitivity (Se) and specificity (Sp) of FDG-PET for the diagnosis of large-vessel inflammation were calculated from each included individual study, and then pooled for meta-analysis with a random effects model. <h3>Results</h3> 21 studies (413 patients, 299 controls) were included in the systematic review. FDG-PET showed FDG vascular uptake in 70% (288/413) of patients and 7% (22/299) of controls. Only vascular uptake equal or higher than the liver uptake was significantly different between GCA/TA patients and controls (p&lt;0.001). The meta-analysis of GCA patients (4 studies, 57 patients), shows that FDG-PET has high Se and Sp for the diagnosis of large-vessel inflammation in GCA patients in comparison to controls, with a pooled Se at 90% (95%CI,0.79-0.96) and a pooled Sp at 98% (95% CI,0.94-0.99). The meta-analysis of TA patients (7 studies, 191 patients), shows that FDG-PET has a pooled Se at 87% (95%CI,0.78- 0.93) and Sp at 73% (95%CI,0.63- 0.81) for the assessment of disease activity in TA, with Sp to 84%, with studies using NIH criteria as disease activity assessment scale. <h3>Conclusions</h3> FDG-PET showed good performances for the diagnosis of large-vessel inflammation, with higher accuracy in GCA compared to TA patients. A visual analysis of vascular uptake, equal or higher than the liver uptake, appears as the best criteria for the diagnosis of large-vessel vasculitis. <h3>Disclosure of Interest</h3> None declared
The Medical Treatment of Gallstones.
Authors: L Pedersen
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pretreatment COX-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy
Authors: H. Kobayashi, Y. Hashiguchi, H. Ueno, E. Shinto, Y. Kajiwara, H. Lenz, K. D. Danenberg, P. V. Danenberg, H. Mochizuki
Journal: Journal of Clinical Oncology (2006)

3610 Background: Neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision has become a standard therapy for patients with rectal cancer. However, not all patients have a good response to CRT. Therefore, it is useful to know what the predictor of chemoradiotherapeutic response is. Cumulative evidence has shown that COX-2 has an important role in the progression of colorectal cancer. The aim of this study was to clarify whether pretreatment COX-2 protein expression was a predictor of histopathologic response in patients with rectal cancer treated with preoperative short-term chemoradiotherapy. Methods: Fifty-two patients with lower rectal cancer received short-term preoperative chemoradiotherapy (20 Gy given in 5 daily doses of 4 Gy and administration of Tegafur/Uracil 400mg/day during the same period), followed by total mesorectal excision at National Defense Medical College from 2001 to 2005. COX-2 expression before and after CRT was measured by immunoshistochemistry. The specimens were graded based on the intensity and extent of staining. Tumor regression grading (TRG) was also evaluated (TRG 4, complete regression; TRG 3, regression &gt; 50%; TRG 2, 25% to 50%; TRG 1, &lt; 25%; and TRG 0, no regression). The correlation between COX-2 expression and tumor regression was analyzed. Results: The patient characteristics were as follows: the male:female ratio was 36:16; median age was 62. The Median postoperative follow-up period was 30 months. Two patients had pathological complete response. Good response (TRG 3 + 4) was found in 57.7% of the resected specimens. COX-2 was positive in 80.8% of patients before CRT while in 100% after CRT. The rates of good response (TRG 3 + 4) in patients with and without COX-2 expression were 50% and 90%, respectively (p = 0.021). Conclusions: Patients without pretreatment COX-2 expression were more likely to demonstrate good response to treatment than those with COX-2 expression. Pretreatment COX-2 protein expression can predict response of CRT in patients with rectal cancer. [Table: see text]